Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.
Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck
The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker
Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)